Holen Sie sich die Stockscreener-App
3.085
2.99%
-0.095
Schlusskurs vom Vortag:
$3.18
Offen:
$3.19
24-Stunden-Volumen:
4,659
Relative Volume:
0.24
Marktkapitalisierung:
$9.06M
Einnahmen:
$556.00K
Nettoeinkommen (Verlust:
$-5.28M
KGV:
-1.4416
EPS:
-2.14
Netto-Cashflow:
$-6.23M
1W Leistung:
+4.22%
1M Leistung:
-5.90%
6M Leistung:
-23.83%
1J Leistung:
+20.98%
1-Tages-Spanne:
$3.0802
$3.21
1-Wochen-Bereich:
$2.80
$3.29
52-Wochen-Spanne:
$1.27
$9.4699
Cyclerion Therapeutics Inc Stock (CYCN) Company Profile
Firmenname
Cyclerion Therapeutics Inc
Sektor
Branche
Telefon
617-621-7722
Adresse
301 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie CYCN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYCN
Cyclerion Therapeutics Inc
|
3.1106 | 9.06M | 556.00K | -5.28M | -6.23M | -2.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.55 | 114.39B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
503.38 | 52.99B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
305.42 | 39.91B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
583.64 | 35.70B | 2.58B | 1.06B | -1.28B | 16.33 |
|
BNTX
Biontech Se Adr
|
108.15 | 27.19B | 2.97B | -812.83M | -1.24B | -3.3962 |
Cyclerion Therapeutics Inc Stock (CYCN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-20 | Eingeleitet | Truist | Buy |
| 2021-09-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-03 | Eingeleitet | Credit Suisse | Neutral |
Cyclerion Therapeutics Inc Aktie (CYCN) Neueste Nachrichten
Cyclerion Therapeutics (NASDAQ:CYCN) Trading 6.5% Higher – Time to Buy? - Defense World
Regina Graul, Ph.D., Promoted to Chief Executive Officer - marketscreener.com
Renaissance Technologies LLC Invests $34,000 in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) - Defense World
Cyclerion partners with Guggenheim for $20M stock sale By Investing.com - Investing.com Nigeria
Cyclerion partners with Guggenheim for $20M stock sale - Investing.com Australia
Cyclerion Therapeutics Enters $20M Sales Agreement - TipRanks
CYCN: Company Stock Sale Proceeds Exclude Firm's Benefit | CYCN Stock News - GuruFocus
Head to Head Survey: NewAmsterdam Pharma (NASDAQ:NAMS) vs. Cyclerion Therapeutics (NASDAQ:CYCN) - Defense World
Dementia Market Expected to Experience Major Growth by 2032, According to DelveInsight | Charsire Biotech Corp, ProNeurogen Therapeutics, Resverlogix, Cyclerion Therapeutics, CSPC-NBP - Barchart
Akebia Therapeutics, Inc. SEC 10-K Report - TradingView
Top Gainers Today: Reborn Coffee (REBN) Leads with a 65% Surge, Cyclerion (CYCN) and Signing Day Sports (SGN) Follow – market - HPBL
3 US Penny Stocks With Market Caps Over $10M To Consider - Simply Wall St
Cyclerion Therapeutics Inc (NASDAQ: CYCN) Is The Number One Stock Currently Moving. - Stocks Register
Market Recap Check: Cyclerion Therapeutics Inc (CYCN)’s Negative Finish at 4.19, Up/Down -21.24 - The Dwinnex
Small Cap Stocks To ConsiderFebruary 02nd - MarketBeat
Cyclerion Therapeutics announces mixed shelf offering - MSN
Cyclerion Therapeutics Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
Check out these key findings about Cyclerion Therapeutics Inc (CYCN) - SETE News
3 Penny Stocks to Watch Now, 2/4/25 - TipRanks
A company insider recently sold 357,880 shares of Cyclerion Therapeutics Inc [CYCN]. Should You also Consider to Sale? – Knox Daily - Knox Daily
Analyzing CYCN’s current quarter earnings projections - US Post News
Biotech Alert: Searches spiking for these stocks today - TipRanks
Cyclerion’s Stock Surge: A Buying Opportunity? - timothysykes.com
Stock summary: Cyclerion Therapeutics surged by 41.01% over the past five days - Business Upturn
Stock market today: Signing Day Sports +62.89%, Cyclerion Therapeutics +57.43% among top gainers in early trading - Business Upturn
Top Premarket Gainers -January 31, 2025 at 07:32 am EST - Marketscreener.com
Finanzdaten der Cyclerion Therapeutics Inc-Aktie (CYCN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.47%
0.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):